

Why test?^{6, 8}



Adhere to ESMO guideline recommendations, which base the use of cytotoxics and biologicals on molecular profile



Gain a deeper knowledge of the impact and clinical relevance of mutations



Promote enrolment of patients into clinical trials with new targeted approaches



Improve outcomes for patients with mCRC

Test for mutations today

6. VanCutsem E, *et al. Ann Oncol* 2016;27:1386–422.

8. Cervantes A, *et al. Ann Oncol* 2023;34(1):10-32.